PMC:2848222 / 3920-4271
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2848222","sourcedb":"PMC","sourceid":"2848222","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2848222","text":"Mutations in both EGFR and K-ras will promote the progression of resistance to anti-EGFR targeting therapy. Limited data in the Chinese population prompted this study, which was performed to explore mutations in EGFR and K-ras gene in Chinese patients with CRC and provide evidence for the efficacy-prediction of EGFR targeting therapeutic strategies.","tracks":[]}